Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1
Viking Therapeutics has started testing a new weight loss drug, VK3019, which targets the amylin pathway, a new approach in the weight loss market dominated by Eli Lilly and Novo Nordisk.
Intelligence analysis by Llama
Viking Therapeutics is trying to compete with Eli Lilly and Novo Nordisk in the weight loss market with its new drug VK3019, which targets the amylin pathway, a new approach in the industry.
Imagine your body has a special button that helps you feel full. Viking Therapeutics is trying to find a new way to press that button to help people lose weight. They're testing a new medicine that targets a different pathway in the body to produce weight loss effects.
Analysis
A New Approach in the Weight Loss Market
Viking Therapeutics has announced the start of a phase 1 trial for its new weight loss drug, VK3019. This drug targets the amylin pathway, a new approach in the weight loss market dominated by Eli Lilly and Novo Nordisk. The amylin pathway is adjacent to the GLP-1 pathway, which is already targeted by several weight loss medications, including Ozempic and Wegovy. VK3019 is a dual amylin and calcitonin receptor agonist, which means it targets two different receptors in the body to produce weight loss effects. The combination of these two receptors is expected to yield metabolic effects that amylin alone does not. Preclinical animal model data showed that the combination led to up to 8% weight reduction against controls.
A Challenging Market
The weight loss market is a highly competitive space, with several established players, including Eli Lilly and Novo Nordisk. These companies have already developed and marketed several weight loss medications, including GLP-1 agonists and amylin receptor agonists. Eli Lilly's eloralintide, for example, has shown promising results in phase 2 trials, with mean weight reductions of 9.5% to 20.1% after 48 weeks. Novo Nordisk's cagrilintide has also shown impressive results, with 11.8% weight loss against 2.3% for placebo over a 68-week period. Viking Therapeutics' VK3019 will need to be substantially more effective or more pleasant to take if the biotech is going to secure a large share of the market.
A Risky Bet
Viking Therapeutics is trying to assemble what both incumbents built years ago. That means VK3019 is going to need to be substantially more effective or more pleasant to take if the biotech is going to secure a large share of the market. It's certainly possible -- but it's very risky to bet on it.
Key points
- Viking Therapeutics has started testing a new weight loss drug, VK3019, which targets the amylin pathway.
- The amylin pathway is adjacent to the GLP-1 pathway, which is already targeted by several weight loss medications.
- VK3019 is a dual amylin and calcitonin receptor agonist, which means it targets two different receptors in the body to produce weight loss effects.
- The combination of these two receptors is expected to yield metabolic effects that amylin alone does not.
- Preclinical animal model data showed that the combination led to up to 8% weight reduction against controls.
If VK3019 is successful, it could potentially disrupt the market share of Eli Lilly and Novo Nordisk, and provide a new treatment option for people struggling with weight loss. Additionally, Viking Therapeutics' shares could see meaningful gains if the company is able to secure a large share of the market.
However, the weight loss market is highly competitive, and Viking Therapeutics' new approach with VK3019 may not be enough to compete with the established players. Additionally, the company's shares may be at risk if the trial results are not as promising as expected.
